Curative Biotechnology, Inc. (CUBT)
OTCMKTS · Delayed Price · Currency is USD
0.0089
-0.0003 (-3.26%)
Aug 1, 2025, 1:50 PM EDT

Curative Biotechnology Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 20202016 - 2020
Period Ending
Mar '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2016 - 2020
Selling, General & Admin
1.862.331.571.964.214.6
Upgrade
Research & Development
0.010.010.272.40.78-
Upgrade
Operating Expenses
1.962.441.934.4654.6
Upgrade
Operating Income
-1.96-2.44-1.93-4.46-5-4.6
Upgrade
Interest Expense
-0.98-1.12-1.36-0.92-0.18-0.03
Upgrade
Other Non Operating Income (Expenses)
0000--
Upgrade
EBT Excluding Unusual Items
-2.94-3.56-3.29-5.38-5.17-4.64
Upgrade
Asset Writedown
----0-0.02-0.03
Upgrade
Other Unusual Items
---0.67--0.15-
Upgrade
Pretax Income
-2.94-3.56-3.96-5.38-5.34-4.67
Upgrade
Net Income
-2.94-3.56-3.96-5.38-5.34-4.67
Upgrade
Preferred Dividends & Other Adjustments
0.620.091.860.0913.480
Upgrade
Net Income to Common
-3.56-3.66-5.82-5.47-18.82-4.67
Upgrade
Shares Outstanding (Basic)
915908662572501327
Upgrade
Shares Outstanding (Diluted)
915908662572501327
Upgrade
Shares Change (YoY)
-37.11%15.76%14.18%53.36%-41.32%
Upgrade
EPS (Basic)
-0.00-0.00-0.01-0.01-0.04-0.01
Upgrade
EPS (Diluted)
-0.00-0.00-0.01-0.01-0.04-0.01
Upgrade
Free Cash Flow
-0.95-1.02-0.49-1.5-1.61-0.19
Upgrade
Free Cash Flow Per Share
-0.00-0.00-0.00-0.00-0.00-0.00
Upgrade
EBITDA
-1.87-2.35-1.84-4.37-5-4.6
Upgrade
D&A For EBITDA
0.090.090.090.0900.01
Upgrade
EBIT
-1.96-2.44-1.93-4.46-5-4.6
Upgrade
Updated Nov 30, 2022. Source: S&P Global Market Intelligence. Standard template. Financial Sources.